Currently, the regulatory relationship and mechanisms between BRD7 and PD-L1 in NPC, as well as the relationship between BRD7 and anti-tumor immunity, remain unclear; further exploration is needed to determine whether BRD7 can serve as a new therapeutic target to enhance the efficacy of immunotherapy. This evidence concerns the gene CD274 and neoplasm.